Medical

Pneumagen announced the initiation of a Phase 2 challenge study of its Neumifil multivalent carbohydrate binding module (mCBM) nasal spray, which is the company is developing as a universal treatment for influenza, RSV, and COVID-19. … Read more . . .

According to Bharat Biotech, two recently completed Phase 3 trials of its BBV154 intranasal COVID-19 vaccine demonstrated the safety and tolerability of the recombinant replication-deficient adenovirus vectored vaccine and as well as its ability to… Read more . . .

Aridis Pharmaceuticals said that its AR-701 inhaled monoclonal antibody cocktail effectively reduced viral load in rhesus macaques infected with SARS-CoV-2 and protected against lung disease in those animals over a 5-day period. The company received… Read more . . .

Opiant Pharmaceuticals said that it has received an additional $2.1 million from the US Biomedical Advanced Research and Development Authority (BARDA) to support regulatory activities related to its OPNT003 intranasal nalmefene for the treatment of opioid overdose. BARDA had… Read more . . .

Verona Pharma said that the Phase 3 ENHANCE-2 trial of nebulized ensifentrine for treatment of COPD met its primary endpoint, with an average change from baseline in FEV1 AUC, 0-12 hours post dose, of 94… Read more . . .

Krystal Biotech said that the FDA has cleared an IND submitted by the company at the beginning of July 2022 and that it now intends to initiate a Phase 1 trial of its KB407 nebulized… Read more . . .

ACM Biolabs has announced the initiation of a Phase 1 trial of its ACM-001 vaccine candidate against SARS-CoV-2. The SAD study will compare ACM-001 to an intramuscular vaccine as a booster in 80 healthy adults… Read more . . .